Jeffrey Dayno, MD
About Jeffrey Dayno, MD
Jeffrey M. Dayno, M.D., is the President and CEO with a background in neurology and extensive experience in the pharmaceutical industry, including leadership roles at Merck & Co., Cephalon, and ViroPharma.
Jeffrey M. Dayno, M.D. - President and CEO
Jeffrey M. Dayno, M.D. currently serves as the President and Chief Executive Officer. He brings a wealth of experience from both clinical and academic medicine, as well as the pharmaceutical industry. Dr. Dayno has held significant leadership roles at major companies such as Merck & Co., Cephalon, and ViroPharma. His extensive expertise positions him as a key leader in the evolving pharmaceutical landscape.
Jeffrey M. Dayno, M.D. Education and Medical Training
Jeffrey M. Dayno earned his medical degree from Temple University School of Medicine. Following medical school, he completed his residency training in Neurology at Temple University Hospital. Expanding his specialization, Dr. Dayno completed a fellowship in Stroke and Cerebrovascular Disorders at Henry Ford Hospital. This rigorous education provided a solid foundation for his subsequent career in both clinical and academic settings.
Jeffrey M. Dayno, M.D. Experience in Patient Care and Teaching
Dr. Dayno has 10 years of experience in patient care and teaching in clinical and academic medicine. This period involved direct patient interactions and educational responsibilities, allowing him to develop a deep understanding of clinical practices and the nuances of medical education.
Jeffrey M. Dayno, M.D. Pharmaceutical Industry Leadership
Over a span of 25 years, Jeffrey M. Dayno, M.D. has played pivotal roles in the pharmaceutical industry. His leadership positions at Merck & Co., Cephalon, and ViroPharma have allowed him to contribute significantly to the industry. He has served as Principal Investigator on numerous clinical trials, providing critical insights and driving forward important medical research.
Jeffrey M. Dayno, M.D. Board Memberships and Advisory Roles
Dr. Dayno's professional influence extends into various advisory and board roles. He serves on the Board of Emalex Biosciences, the Board of Visitors of the Lewis Katz School of Medicine at Temple University, and the Board of Advisors for Life Science Cares Philadelphia. His expertise is also recognized by the FDA, where he has served as the Industry Representative for the Peripheral and Central Nervous System Drugs Advisory Committee and participated in several advisory panels.
Jeffrey M. Dayno, M.D. Publications and Lectures
Jeffrey M. Dayno, M.D. has published and lectured extensively on topics including evolving pharma business models, value creation, impact, and neurology. His contributions to the field are widely recognized, including his inclusion in the PharmaVoice 100 list in 2023. These activities highlight his ongoing commitment to advancing medical knowledge and practice.